All Biomarkers articles
-
NewsBlood test for protein misfolding identifies Alzheimer’s risk years before symptoms
A blood-based biomarker measuring amyloid beta protein misfolding has demonstrated superior predictive accuracy for pre-symptomatic Alzheimer’s disease compared with p-tau 217, achieving an AUC of 0.87 when combined with genetic and demographic data.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
ArticleHow spatial biology is tracking antibody drugs inside tumours
Many antibody therapies fail to reach all cancer cells within solid tumours. Researchers have developed a spatial biology technique that maps antibody distribution alongside the tumour microenvironment to investigate why.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
NewsSpatial map reveals hidden complexity of bladder cancer tumours
Researchers at MD Anderson Cancer Center have used spatial transcriptomics to chart the internal architecture of muscle-invasive bladder cancer, revealing that luminal and basal cancer cell programmes coexist within single tumours – a finding with significant implications for treatment stratification.
-
NewsCrown Bioscience joins C-Path coalition advancing regulatory NAMs acceptance
Crown Bioscience has joined the Critical Path Institute’s New Approach Methodologies Developer Coalition, bringing patient-derived model expertise and biomarker capabilities to efforts aimed at establishing regulatory qualification frameworks for human-relevant research tools.
-
NewsGene therapy restores key features in fragile X syndrome mouse model
Researchers at Cincinnati Children’s have demonstrated that AAV-mediated delivery of the human FMR1 gene can restore FMRP expression and reverse multiple disease-related features in a fragile X syndrome mouse model, offering a promising preclinical foundation for future clinical trials.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsNew BET therapies could help beat resistance in solid cancers
A new review finds that next-generation BET-targeted therapies, including selective inhibitors and PROTACs, are addressing the clinical shortcomings of earlier compounds and reviving interest in this approach for solid tumour treatment.
-
NewsNew BET inhibitors could overcome barriers in solid tumour treatment
A new review examines how advances in drug design, PROTAC degraders and combination therapies are reviving the clinical prospects of BET inhibition in solid tumours, after early-generation compounds were hampered by toxicity, resistance and modest efficacy.
-
NewsATRX mutations reprogram chromatin to drive glioma progression
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
-
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
-
NewsCopper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study
A copper-delivering compound has demonstrated the ability to restore blood-brain barrier clearance mechanisms, reducing amyloid-beta accumulation by 42 percent and improving spatial learning by 44 percent in Alzheimer’s disease models, according to research published in ACS Chemical Neuroscience.
-
ReportContext is everything: how spatial biology is changing our understanding of disease
Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
-
NewsNotch2 enables breast cancer dormancy in protective bone marrow niches
New research has demonstrated how breast cancer cells exploit protective bone marrow niches to remain dormant for years, identifying Notch2 signalling and stem cell-like markers as key regulators of cellular dormancy that could inform therapeutic strategies to prevent relapse.
-
NewsGene-based CIN score predicts breast cancer survival and immunotherapy response
A 13-gene chromosomal instability scoring system developed by Shanghai researchers correlates with survival outcomes and immunotherapy response in breast cancer patients.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.
-
NewsPERM1 protein linked to heart recovery in LVAD patients
A newly identified protein may explain why some failing hearts recover function following mechanical support while others do not.